Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box–Behnken Design Optimization

Background: Ursodeoxycholic acid (UDCA) is a therapeutic agent used for the treatment of cholestatic hepatobiliary diseases in pediatric patients. It is a bile acid that presents high lipophilicity, and it belongs to Class II of the Biopharmaceutical Classification System (BCS), which exhibits low w...

Descripción completa

Detalles Bibliográficos
Autores principales: Boscolo, Oriana, Flor, Sabrina, Salvo, Leandro, Dobrecky, Cecilia, Höcht, Christian, Tripodi, Valeria, Moretton, Marcela, Lucangioli, Silvia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458560/
https://www.ncbi.nlm.nih.gov/pubmed/37631251
http://dx.doi.org/10.3390/pharmaceutics15082037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458560/
https://www.ncbi.nlm.nih.gov/pubmed/37631251
http://dx.doi.org/10.3390/pharmaceutics15082037

Ejemplares similares